UK Markets closed

Genfit SA (GNFTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.72000.0000 (0.00%)
As of 12:05PM EDT. Market open.
Sign in to post a message.
  • G
    Gerald
    I'm long and lonely here. From pre-NASH collapse days. Unusual volume here yesterday and today so far.
  • B
    Bert
    What's cooking? Unusual volume in Paris. Take over or what?
  • A
    Anonymous
    Very quiet board...

    Sometimes, still waters run deep :-)

    Anyone looking at Genfit and elafibranor for the first time (bearing in mind that the Big catalyst is the phase 3 readout in late 2019) might like to know that elafibranor was recently awarded Breakthrough Therapy status in PBC.

    Also, Barclays initiates coverage on 224 at Overweight with a PT of 55 USD (120% upside)
  • A
    Aly
    12/19/2019 Show Full StoriesSend Info

    GNFT09:10 Genfit analyst commentary at Roth Capital 

    Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH. Roth Capital analyst Yasmeen Rahimi said there is an "urgent need" for non-invasive testing in non-alcoholic steatohepatitis, or NASH, and her call with Donna Cryer of the Global Liver Institute, and Dr. Suneil Hosmane, Genfit's EVP and Global Head of Diagnostics, provided a better view into the utility and diagnostic value of the company's NIS4 NIT toolkit, which combines four biomarkers to diagnose fibrosis with high predictability. The analyst, who sees Genfit "unlocking the power of non-invasive NASH diagnosis," keeps a Buy rating and EUR70 price target on the company's shares following her expert call.
  • J
    Jason
    Analysts just upgraded with 120% upside

    Check out GNFT Analyst Price Target $11.81 on TipRanks http://www.tipranks.com/ios/pages/stocks/GNFT/price-target
  • a
    adf
    Nicolaus analyst Derek Archila has a hold rating on GNFT, arguing that the stock is now likely to remain range bound until management provides an update in the fall for elafibranor in NASH.
    However, there is a glimmer of hope- elafibranor’s program in primary biliary cholangitis (PBC). Archila thinks here GNFT has solid proof-of-concept data from both an efficacy and safety perspective, and that this could provide a floor for shares.
  • A
    Anonymous
    See Forbes article today: Is Genfit Primed to Win the NASH Derby?
  • T
    Terminal Gravity
    This company is starting to interest me. Recent disappointment but trading below cash. Surely their IP is worth something? Also, technicals are showing an uptick in MFI and MACD just went positive.
  • H
    HADRIAN G
    I'm trying to research this company

    I see A positive article about earnings on April 17 https://finance.yahoo.com/news/why-genfit-gnft-stock-might-124312126.html

    is elafibranor a factor in the earnings from their other operations?

    I'm assuming they will continue to operate in these other areas albeit interrupted by the Pandemic.

    What Say you?
  • A
    Anonymous
    Genfit licenses elafibranor development and commercialization for the Greater China region.

    https://endpts.com/genfit-goes-to-china-with-a-deal-worth-up-to-228m-for-nash-drug/

    (Article complete with amusing analyst commentary that confuses NASH with steatosis)
    Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to develop its flagship exper
    Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to develop its flagship exper
    endpts.com
  • b
    boris
    Genfit: GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS
    www.globenewswire.com
  • T
    Titus
    The company should look into doing a collab work with Galt. A combo therapy for F5-F6. A perfect partnership for NASH awaits and a chance for both to corner all spectrums Fibrosis as a combo therapy.
  • C
    Christophe
    Kepler Cheuvreux 20/2 : "Elafibranor remains the only drug in late stage development that is effective against NASH symptoms, which might make it the backbone therapy for NASH"
  • G
    Gerald
    6 times average volume, up 12.36% on the day and nobody even notices here.
    This is where money big time is about to be made and I have the floor all to myself.
  • s
    stocktracker000
    Stay out of this for 1-3 weeks. It's tempting because of price fall but past prices do not matter...

    Considering low trading volume, it will take a while for all the sellers to get out...

    You have been warned!

    Been there and done that...

    Good Luck to all and do your due diligence always...
  • M
    Marjan
    I believe, after a good study ! Why GENFIT !!!

    Cymabay stock crashed 76% seladelpar having flunked a phase II Nash study in June; However looking at drug structural differences (Seladelpar has 3 Fluorine atoms) leads me to think this is not from PPAR δ inhibition but a direct liver tox effect from the drug. In agreement with this thinking is that previous liver biopsies from patients using Elafibranor have detected no liver abnormalities suggestive of autoimmunity. Leads me to believe it will be successful in NASH and PBC.

    GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

    Elafibranor Molecular Formula: C22H24O4S sulfur instead of flora is a good sign !!!!!
  • m
    mac
    GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
  • M
    MWirth13
    Ruh-roh Intercept! LONG GNFT
    https://endpts.com/intercepts-nash-decision-date-is-deferred-ema-investigates-safety-of-leo-pharma-gel/

    January 17, 2020 09:56 AM EST Endpoints Staff Protocols
    Intercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel
    → The first drugmaker tipped to win approval for a NASH therapeutic is going to have to wait three months longer. The FDA is now expected to make its final decision on Intercept Pharmaceuticals‘ obeticholic acid by June 26. The delay was attributed to a major amendment — additional information was provided by the company in response to FDA requests — as well as to accommodate an advisory committee meeting, Intercept said in a filing on Friday. Last month, the FDA notified the company it tentatively intended to hold the adcomm on April 22 — so a delay to the March PDUFA was in any case expected.
    → The first drugmaker tipped to win approval for a NASH therapeutic is going to have to wait three months longer. The FDA is now expected to make its final decision on Intercept Pharmaceuticals' obeticholic acid by June 26. The delay was attributed t
    → The first drugmaker tipped to win approval for a NASH therapeutic is going to have to wait three months longer. The FDA is now expected to make its final decision on Intercept Pharmaceuticals' obeticholic acid by June 26. The delay was attributed t
    endpts.com
  • B
    Bemo
    Better look at the MACD Line and Histogram. Their the "trend indicator", not RSI or Williams %R. Three of you were wrong.
  • S
    SpaceFlower
    GNFT first NASH therapy to market, ignore the toxic ICPT bashers that one will never make it to market.